Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Silverman

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
BMC Medical Genomics|November 23, 2016
"A rising tide lifts all boats": establishing a multidisciplinary genomic tumor board for breast cancer patients with advanced diseaseMichelle L McGowan, Roselle S Ponsaran, Paula Silverman, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|July 29, 2016
Understanding age and race disparities in the application of sentinel lymph node biopsy in breast cancerArchana Radhakrishnan, Paula Silverman, Craig Evan Pollack, et al.
Human Pathology|June 13, 2018
Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinomaAparna Harbhajanka, Satyapal Chahar, Kristy Miskimen, et al.
Breast Cancer Research and Treatment|November 16, 2011
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerElaina M Gartner, Paula Silverman, Michael Simon, et al.
Head & Neck|February 14, 2006
Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology GroupJill Gilbert, Yi Li, Harlan A Pinto, et al.
AJR. American Journal of Roentgenology|April 25, 2012
Neglecting to screen women between the ages of 40 and 49 years with mammography: what is the impact on breast cancer diagnosis?Mallory E Kremer, Catherine Downs-Holmes, Ronald D Novak, et al.
Investigational New Drugs|September 14, 2006
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedulesHarold J Burstein, Beth Overmoyer, Rebecca Gelman, et al.
Breast Cancer Research and Treatment|December 14, 2005
Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancerBrenda W Cooper, Tomas Radivoyevitch, Beth A Overmoyer, et al.
The Breast Journal|March 9, 2018
A breast multi-disciplinary genomic tumor board is feasible and can provide timely and impactful recommendationsKaren Tsung, Cheryl L Thompson, Joy M Knight, et al.
Breast Cancer Research and Treatment|May 23, 2014
Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumorsSteven T Sizemore, Gina M Sizemore, Christine N Booth, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
BMC Medical Genomics|November 23, 2016
"A rising tide lifts all boats": establishing a multidisciplinary genomic tumor board for breast cancer patients with advanced diseaseMichelle L McGowan, Roselle S Ponsaran, Paula Silverman, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|July 29, 2016
Understanding age and race disparities in the application of sentinel lymph node biopsy in breast cancerArchana Radhakrishnan, Paula Silverman, Craig Evan Pollack, et al.
Human Pathology|June 13, 2018
Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinomaAparna Harbhajanka, Satyapal Chahar, Kristy Miskimen, et al.
Breast Cancer Research and Treatment|November 16, 2011
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerElaina M Gartner, Paula Silverman, Michael Simon, et al.
Head & Neck|February 14, 2006
Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology GroupJill Gilbert, Yi Li, Harlan A Pinto, et al.
AJR. American Journal of Roentgenology|April 25, 2012
Neglecting to screen women between the ages of 40 and 49 years with mammography: what is the impact on breast cancer diagnosis?Mallory E Kremer, Catherine Downs-Holmes, Ronald D Novak, et al.
Investigational New Drugs|September 14, 2006
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedulesHarold J Burstein, Beth Overmoyer, Rebecca Gelman, et al.
Breast Cancer Research and Treatment|December 14, 2005
Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancerBrenda W Cooper, Tomas Radivoyevitch, Beth A Overmoyer, et al.
The Breast Journal|March 9, 2018
A breast multi-disciplinary genomic tumor board is feasible and can provide timely and impactful recommendationsKaren Tsung, Cheryl L Thompson, Joy M Knight, et al.
Breast Cancer Research and Treatment|May 23, 2014
Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumorsSteven T Sizemore, Gina M Sizemore, Christine N Booth, et al.
Pageof 4